AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Show more

1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom

https://www.astrazeneca.com

Drug Manufacturers - General

Healthcare

Start AI Chat

Market Cap

281.6B

52 Wk Range

$137.22 - $212.71

Previous Close

$181.55

Open

$181.73

Volume

1,881,582

Day Range

$181.16 - $183.81

Enterprise Value

314.7B

Cash

7.675B

Avg Qtr Burn

N/A

Insider Ownership

0.05%

Institutional Own.

65.04%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Imfinzi (durvalumab) +Imjudo (tremelimumab) +platinum-based chemotherapy Details Cancer, Non-small cell lung carcinoma, Lung cancer	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breztri Aerosphere Details Asthma	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Koselugo (selumetinib, MEK inhibitor) Details Cancer, Solid tumor/s, Neurofibromatosis type 1	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu Details Cancer, Breast cancer	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Saphnelo Details Systemic Lupus Erythematosus	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu Details Early-stage HER2+ breast cancer (neoadjuvant)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu/Trastuzumab Deruxtecan (DS-8201a) (HER2-Targeted ADC) Details HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Therapy	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Airsupra (PT027)(albuterol/budesonide) Details Asthma	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi Details Cancer, Bladder cancer	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi/Durvalumab + Bacillus Calmette-Guérin (MEDI4736) (PD-L1 Inhibitor) Details High-Risk Non-Muscle-Invasive Bladder Cancer	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Baxdrostat Details Resistant or uncontrolled hypertension	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Calquence (acalabrutinib) Details Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Farxiga Details Type 2 diabetes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Calquence (acalabrutinib) w/ bendamustine and rituximab Details Cancer, Blood cancer, Mantle cell lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) Details Non-small cell lung carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Truqap (Capivasertib) + Faslodex (fulvestrant) Details Breast cancer, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Datroway (datopotamab deruxtecan) Details Cancer, Breast cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FluMist Quadrivalent (self-administration) Details Influenza	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu Details 1L HER2-positive Metastatic Breast Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultomiris Details Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fasenra Details Coronary Microvascular Dysfunction, Eosinophilic granulomatosis with polyangiitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tezspire (tezepelumab) Details no known indication	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Forxiga (dapagliflozin) Details Heart failure	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi + chemotherapy (as neoadjuvant treatment) Details Cancer, Non-small cell lung carcinoma, Lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu Details Cancer, Solid tumor/s	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tagrisso + chemotherapy Details Lung cancer, Cancer, EGFR-mutated advanced lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tagrisso Details Non-small cell lung carcinoma, Cancer, Lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Voydeya (Danicopan) Details Paroxysmal nocturnal hemoglobinuria	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Calquence (acalabrutinib) + venetoclax +/- obinutuzumab Details Cancer, Blood cancer, Chronic lymphocytic leukemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lynparza w/ abiraterone and prednisone or prednisolone Details Solid tumor/s, Cancer, Castration-resistant prostate cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi (durvalumab) Details Lung cancer, Cancer, Small cell lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Beyfortus (Nirsevimab) Details Respiratory syncytial virus, Respiratory virus, Viral infection	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soliris (eculizumab) Details Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi + Lynparza Details Cancer, Solid tumor/s, Endometrial cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Camizestrant + CDK 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) vs AI + CDK 4/6 inhibitor Details Advanced HR-positive breast cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Truqap/Capivasertib (N/A) (AKT Inhibitor) Details PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Andexxa (andexanet alfa) Details Intracranial haemorrhage	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vaxzevria (ChAdOx1-S [Recombinant],formerly AZD1222 Details COVID-19	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Saphnelo Details Idiopathic pulmonary fibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tezspire (tezepelumab) Details Chronic rhinosinusitis with nasal polyps	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tezspire (tezepelumab) Details Asthma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu Details Cancer, Non-small cell lung carcinoma (1L NSCLC)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ENHERTU + rilvegostomig or pembrolizumab Details Endometrial cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Orpathys + Tagrisso Details Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tozorakimab Details Respiratory conditions, Acute respiratory distress syndrome, Lung disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi (durvalumab) Details Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fasenra Details Chronic rhinosinusitis with nasal polyps	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tagrisso Details Non-small cell lung carcinoma, Cancer, Lung cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Capivasertib Details Breast cancer, Cancer, Triple-negative breast cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tozorakimab (MEDI3506) (IL-33 Antibody) Details Chronic Obstructive Pulmonary Disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi/Durvalumab + Imjudo/Tremelimumab-Actl + Enfortumab Vedotin (MEDI4736) (Immunotherapy ADC) Details Muscle-Invasive Bladder Cancer (Cisplatin-Ineligible Or Declined)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efzimfotase Alfa (ALXN1850) (Enzyme Replacement) Details Hypophosphatasia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Farxiga Details Acute myocardial infarction	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi comb w/ chemotherapy Details Cancer, Biliary Tract Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi (mono/combo) Details Cancer, Liver cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ENHERTU Details Gastroesophageal Junction (GEJ) Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultomiris/Ravulizumab (ALXN1210) (C5 Inhibitor) Details IgA Nephropathy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breztri Aerosphere (N/A) (Triple Therapy) Details Chronic Obstructive Pulmonary Disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultomiris/Ravulizumab (ALXN1210) (C5 Inhibitor) Details IgA Nephropathy	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Anselamimab (CAEL-101) Details Amyloid light chain amyloidosis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sipavibart (AZD3152) Details COVID-19	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi (durvalumab) + SoC (FLOT) chemotherapy Details Cancer, Gastroesophageal junction tumors, Gastric cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Breztri Aerosphere/Budesonide-Glycopyrrolate-Formoterol (N/A) (Triple Inhaled Therapy) Details Chronic Obstructive Pulmonary Disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efzimfotase Alfa (N/A) (Enzyme Replacement) Details Hypophosphatasia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
roxadustat Details Myelodysplastic syndrome, Anemia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Fasenra Details Coronary Microvascular Dysfunction	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imfinzi/Durvalumab (MEDI4736) + Orpathys/Savolitinib (AZD6094) (PD-L1/MET Combo) Details MET-Positive Advanced Papillary Renal Cell Carcinoma	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AZD7442 (tixagevimab/cilgavimab) Details COVID-19	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY/Datopotamab Deruxtecan (DS-1062) (TROP2 ADC) Details TROP2 NMR-Positive Advanced Nonsquamous NSCLC	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Enhertu/Trastuzumab Deruxtecan (DS-8201a) (HER2-Targeted ADC) Details HER2-Expressing Advanced Epithelial Ovarian Cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FPI-2265 Details Prostate cancer, Cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
balcinrenone/dapagliflozin (MR modulator + SGLT2 inhibitor) Details Cancer, Chronic kidney disease, Heart failure	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AZD0780 (oral PCSK9 inhibitor) Details Dyslipidemia	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Baxdrostat Details Chronic kidney disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tozorakimab (IL-33 ligand mAb) Details Diabetic Kidney Disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Baxdrostat Details Pulmonary hypertension	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Volrustomig (N/A) (Bispecific Antibody) Details Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) Details Resectable, early-stage (stage IIA-IIIB) NSCLC	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tozorakimab (MEDI3506) (IL-33 Antibody) Details Asthma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Orpathys/Savolitinib (AZD6094) (MET Inhibitor) Details MET-Amplified Gastric Cancer Or Gastroesophageal Junction Adenocarcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Baxdrostat Details Primary aldosteronism	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LB-001 Details Methylmalonic acidemia, Genetic disorder, Rare genetic disease	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Puxi-Sam/Puxitatug Samrotecan (AZD8205) (B7-H4 ADC) Details Relapsed Or Metastatic B7-H4-Positive Endometrial And Ovarian Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Puxitatug Samrotecan (AZD8205) (B7-H4 ADC) Details Relapsed Or Metastatic B7-H4-Positive Endometrial Cancer And Ovarian Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) + immunotherapy (durvalumab, rilvegostomig or volrustomig) +/- carboplatin Details Advanced or metastatic NSCLC	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ECC5004 Details Obesity, Type 2 diabetes	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) Details Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FPI-2068 Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FPI-2059 Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DATROWAY® (datopotamab deruxtecan) + KEYTRUDA® (pembrolizumab) Details Non-small cell lung carcinoma, Lung cancer, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NT-175 (TCR Therapy) Details TP53 R175H-Mutated Unresectable, Advanced Or Metastatic Solid Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FPI-1434 (targeted alpha radioimmunoconjugate) Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AZD3470 (PRMT5 Inhibitor) Details Relapsed Or Refractory Classic Hodgkin Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AZD3470 (PRMT5 Inhibitor) Details Relapsed Or Refractory Classic Hodgkin Lymphoma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NT-175 (TCR Therapy) Details TP53 R175H-Mutated Unresectable Advanced Or Metastatic Solid Tumors	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultomiris/Ravulizumab (ALXN1210) (C5 Inhibitor) Details Cardiac Surgery-Associated Acute Kidney Injury	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultomiris/Ravulizumab (ALXN1210) (C5 Inhibitor) Details Cardiac Surgery-Associated Acute Kidney Injury	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.